Bimekizumab Efficacy and Safety in Patients With Moderate to Severe Plaque Psoriasis Who Switched From Adalimumab, Ustekinumab, or Secukinumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Br J Dermatol 2023 Feb 22;188(3)330-340, G Kokolakis, RB Warren, B Strober, A Blauvelt, L Puig, A Morita, M Gooderham, A Körber, V Vanvoorden, M Wang, D de Cuyper, C Madden, N Nunez Gomez, M LebwohlFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.